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Bacillus coagulansGBI-30, 6086 is a safe strain, already available on the market, and characterized by certified beneficial effects.
The draft genome sequence presented here constitutes the first pillar toward the identification of the molecular mechanisms re-
sponsible for its positive features and safety.
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Bacillus coagulans strain GBI-30, 6086 is a safe, spore-formingstrain, as testified by theGRAS (Generally RecognizedAs Safe)
status received in 2012 from the United States FDA; the strain is
authorized for human consumption and already available in a
wide selection of functional foods or as dietary supplement (1).
This strain is characterized by certified beneficial effects in gastro-
intestinal disorders, such as irritable bowel syndrome, intestinal
gas, and colitis (2, 3, 4, 5); in rheumatoid arthritis (6); and in
common viral infections of the respiratory tract (7). As a spore-
former,B. coagulansGBI-30, 6086 can be incorporated into foods,
where it can survive themild heat-treatments used for sterilization
andwithstand the harsh conditions of the gastrointestinal tract,
i.e., the low pH of the gastric barrier (8).
Here we report the draft genome sequence of B. coagulans
GBI-30, 6086 in order to unveil the genetic basis of its safety
and probiosis. To the best of our knowledge, this is the first
published fully assembled genome of a commercial B. coagu-
lans probiotic strain.
The whole-genome sequencing was performed using the Illu-
mina GAIIx platform at CRA-Genomics Research Centre (Pi-
acenza, Italy) with a paired-end library; the reads were de novo
assembled using the CLC Genomic Workbench version 7.0. The
genome sequence was annotated by the NCBI Prokaryotic Ge-
nomes Annotation Pipeline.
A total of 14,500,000 paired-end reads of 110-bp length on
average (genome coverage of 840) were assembled into 224 con-
tigs (N50 length of 44,706 bp), with the largest assembled contig of
125,999-bp length. The draft genome consists of 3,458,655 bp
with GC % content of 46.38.
A total of 3,373 geneswere predicted, of which 3,197 are coding
sequences (CDS), 18 are rRNAs, and 82 are tRNAs; 79 were iden-
tified to be pseudogenes, and 1 was identified as ncRNA. The
genome also contains 3 CRISPR arrays, which could be involved
as a defense mechanism toward foreign genetic elements (9).
The strain is predicted to encode for about 500 proteins in-
volved in central carbohydrate metabolism, including glycolysis,
pentose phosphate, and xylose utilization pathways (9, 10). As
expected, about 80 genes regarding dormancy and sporulation
were annotated, in particular, spore DNA protection, sporula-
tion mechanisms, spore core dehydration, and spore germina-
tion. Furthermore, the genome contains determinants in-
volved in the adhesion (i.e., fibronectin- and mucus-binding
proteins) and active metabolism in the host (as a biotin biosyn-
thesis pathway).
The complete genome of B. coagulans GBI-30, 6086 obtained
in the present study will contribute to a wider and deeper insight
into the safety features of this strain, and the comparative genomic
analysis with other Bacillus strains genomes (11, 12, 13) might
shed new light on the molecular mechanisms at the basis of its
probiotic and beneficial properties.
Nucleotide sequence accessionnumbers.Thiswhole-genome
shotgun project has been deposited inDDBJ/EMBL/GenBank un-
der the accession number JPSK00000000. The version described
in this paper is the first version, JPSK01000000.
ACKNOWLEDGMENTS
This work was supported by the Italian Ministry for Development in
the framework of the project “Pass-World–pasta e salute nel mondo—
Industria 2015” (MI01_00138). G.S. was also supported by MIUR
(PON02_00186_2937475) in the framework of the project named
“Protocolli innovativi per lo sviluppo di alimenti funzionali” (Pro. Ali.
Fun.).
REFERENCES
1. Cutting SM. 2011. Bacillus probiotics. Food Microbiol. 28:214–220.
http://dx.doi.org/10.1016/j.fm.2010.03.007.
2. Dolin BJ. 2009. Effects of a proprietary Bacillus coagulans preparation on
symptoms of diarrhea-predominant irritable bowel syndrome. Methods
Find. Exp. Clin. Pharmacol. 31:655–659. http://dx.doi.org/10.1358/
mf.2009.31.10.1441078.
3. Hun L. 2009. Bacillus coagulans significantly improved abdominal pain
crossmark
Genome AnnouncementsNovember/December 2014 Volume 2 Issue 6 e01080-14 genomea.asm.org 1
and bloating in patients with IBS. Postgrad. Med. 121:119–124. http://
dx.doi.org/10.3810/pgm.2009.03.1984.
4. Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger
DR. 2009. A prospective, randomized, double-blind, placebo-controlled
parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-
based product on functional intestinal gas symptoms. BMC Gastroen-
terol. 9:85. http://dx.doi.org/10.1186/1471-230X-9-85.
5. Fitzpatrick LR, Small JS, Greene WH, Karpa KD, Farmer S, Keller D.
2012. Bacillus coagulansGBI-30, 6086 limits the recurrence ofClostridium
difficile-induced colitis following vancomycin withdrawal in mice. Gut
Pathog. 4:13. http://www.gutpathogens.com/content/4/1/13.
6. Mandel DR, Eichas K, Holmes J. 2010. Bacillus coagulans: a viable ad-
junct therapy for relieving symptoms of rheumatoid arthritis according to
a randomized, controlled trial. BMC Complement. Altern. Med. 10:1.
http://dx.doi.org/10.1186/1472-6882-10-1.
7. Jurenka JS. 2012. Bacillus coagulans. Altern. Med. Rev. 17:76–81.
8. Barbosa TM, Serra CR, La Ragione RM, Woodward MJ, Henriques AO.
2005. Screening for Bacillus isolates in the broiler gastrointestinal tract.
Appl. Environ. Microbiol. 71:968 –978. http://dx.doi.org/10.1128/
AEM.71.2.968-978.2005.
9. Su F, Tao F, Tang H, Xu P. 2012. Genome sequence of the thermophile
Bacillus coagulans hammer, the type strain of the species. J. Bacteriol.
194:6294–6295. http://dx.doi.org/10.1128/JB.01380-12.
10. Su F, Xu P. 2014. Genomic analysis of thermophilic Bacillus coagulans
strains: efficient producers for platform bio-chemicals. Scientific Rep.
4:1–10. http://dx.doi.org/10.1038/srep03926.
11. Rhee MS, Moritz BE, Xie G, del Rio TG, Dalin E, Tice H, Bruce D,
Goodwin L, Chertkov O, Brettin T, Han C, Detter C, Pitluck S, Land
ML, Patel M, Ou M, Harbrucker R, Ingrram LO, Shanmugam KT. 2011.
Complete genome sequence of a thermotolerant sporogenic lactic acid
bacterium, Bacillus coagulans strain 36D1. Stand Genomics Sci.
5:331–340. http://dx.doi.org/10.4056/sigs.2365342.
12. Su F, Xu K, Zhao B, Tai C, Tao F, Tang H, Xu P. 2011. Genome
sequence of the thermophilic strain Bacillus coagulans XZL4, an efficient
pentose-utilizing producer of chemicals. J. Bacteriol. 193:6398–6399.
http://dx.doi.org/10.1128/JB.06157-11.
13. Xu K, Su F, Tao F, Li C, Ni J, Xu P. 2013. Genome sequences of two
morphologically distinct and thermophilic Bacillus coagulans strains, H-1
andXZL9. GenomeAnnounc. 1(3):e00254-13. http://dx.doi.org/10.1128/
genomeA.00254-13.
Orrù et al.
Genome Announcements2 genomea.asm.org November/December 2014 Volume 2 Issue 6 e01080-14
